PCVX
$63.62-2.53%
Vaxcyte Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.02%US Stock Market 0.01%Russell 3000 0.01%
PCVX financial statements
The full income statement, balance sheet, and cash-flow statement for Vaxcyte Inc. (PCVX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 111.6M2024-09 124.6M2024-12 128.8M2025-03 129.0M2025-06 129.8M2025-09 130.9M2025-12 143.9M2026-03 144.4M2026-06 148.8M+33.3% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 924M+62.2% | 570M+21.7% | 468M+101.5% | 232M+124.0% | 104M+15.7% | ||
| Research & development | 794M+66.6% | 477M+43.4% | 332M+96.1% | 169M+116.1% | 78.4M+6.6% | |
| Selling, general & administrative | 129M+39.3% | 92.9M+53.1% | 60.7M+52.5% | 39.8M+57.6% | 25.3M+57.7% | |
| General & administrative | 129M+39.3% | 92.9M+53.1% | 60.7M+52.5% | 39.8M+57.6% | 25.3M+57.7% | |
| Operating income | -924M-62.2% | -570M-21.7% | -468M-101.5% | -232M-124.0% | -104M-15.7% | |
| Interest expense | — | 0.00 | 0.00-100.0% | 2.00K-71.4% | 7.00K+0.0% | |
| Interest & investment income | 120M+8.8% | 110M+74.9% | 62.9M+652.8% | 8.36M+2329.1% | 344K+41.0% | |
| Other non-operating income | 37.3M+953.2% | -4.38M-252.5% | 2.87M-67.3% | 8.77M+144.1% | 3.59M+887.1% | |
| Income tax | 0.00 | 0.00 | 0.00 | — | — | |
| -767M-65.2% | -464M-15.3% | -402M-80.0% | -223M-123.3% | -100M-12.2% | ||
| Net income to common | -767M-65.2% | -464M-15.3% | -402M-80.0% | -223M-123.3% | -100M-12.2% | |
| -$5.63-48.2% | -$3.80+8.2% | -$4.14-20.3% | -$3.44-78.2% | -$1.93+36.1% | ||
| EPS (basic) | -$5.63-48.2% | -$3.80+8.2% | -$4.14-20.3% | -$3.44-78.2% | -$1.93+36.1% | |
| Weighted-avg shares (basic) | 136M+11.6% | 122M+25.6% | 97.2M+49.8% | 64.9M+25.0% | 51.9M+75.7% | |
| Weighted-avg shares (diluted) | 136M+11.6% | 122M+25.6% | 97.2M+49.8% | 64.9M+25.0% | 51.9M+75.7% | |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 1.63B-9.0% | 1.79B+63.1% | 1.10B+16.3% | 943M+267.7% | 256M-34.1% | ||
| Cash & equivalents | 174M-55.2% | 388M-2.4% | 397M-52.4% | 835M+1109.9% | 69.0M-82.1% | |
| Short-term investments | 1.39B+2.0% | 1.36B+99.1% | 683M+605.9% | 96.7M-45.4% | 177M | |
| Prepaid expenses | 66.4M+62.8% | 40.8M+159.3% | 15.7M+40.7% | 11.2M+7.7% | 10.4M+270.1% | |
| Other current assets | 1.59M-21.7% | 2.04M-3.7% | 2.11M+6.2% | 1.99M | — | |
| 3.00B-14.5% | 3.51B+149.4% | 1.41B+39.9% | 1.01B+210.2% | 324M-17.4% | ||
| Property, plant & equipment | 257M+30.0% | 198M+148.7% | 79.6M+668.6% | 10.4M+30.2% | 7.95M+143.1% | |
| Operating lease right-of-use | 116M+60.9% | 72.1M+132.6% | 31.0M+45.6% | 21.3M-23.9% | 28.0M+3006.4% | |
| Long-term investments | 882M-36.5% | 1.39B+752.9% | 163M+512.7% | 26.5M-2.1% | 27.1M | |
| Other non-current assets | 119M+84.7% | 64.4M+71.3% | 37.6M+724.6% | 4.55M+11.4% | 4.09M+643.5% | |
| Total non-current assets | 1.38B-20.2% | 1.72B+452.4% | 312M+390.3% | 63.6M-6.4% | 68.0M+1678.9% | |
| 206M+46.8% | 140M-3.5% | 145M+258.6% | 40.5M+41.1% | 28.7M-38.7% | ||
| Accounts payable | 70.9M+46.3% | 48.5M+232.2% | 14.6M+48.9% | 9.79M+44.9% | 6.76M-77.3% | |
| Accrued liabilities | 31.1M+6.7% | 29.1M-51.3% | 59.8M+289.0% | 15.4M+75.0% | 8.79M+133.3% | |
| Current lease liability | 6.12M+4.0% | 5.89M-17.2% | 7.11M+20.4% | 5.91M+12.0% | 5.28M | |
| 317M+54.4% | 205M+22.7% | 167M+218.6% | 52.6M+30.4% | 40.3M-14.2% | ||
| Non-current lease liability | 111M+70.9% | 65.2M+195.0% | 22.1M+83.8% | 12.0M+4.6% | 11.5M | |
| Operating lease liability (total) | 118M+65.4% | 71.1M+143.3% | 29.2M+62.9% | 17.9M+6.9% | 16.8M | |
| Other non-current liabilities | 100K+0.0% | 100K | 0.00-100.0% | 9.00K-90.6% | 96.0K-14.3% | |
| 2.69B-18.8% | 3.31B+166.5% | 1.24B+30.1% | 954M+235.8% | 284M-17.9% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 134K+4.7% | 128K+30.6% | 98.0K+19.5% | 82.0K+46.4% | 56.0K+3.7% | |
| Additional paid-in capital | 4.84B+3.0% | 4.70B+117.0% | 2.16B+46.7% | 1.48B+153.2% | 583M+7.1% | |
| Retained earnings | -2.15B-55.2% | -1.39B-50.2% | -924M-77.0% | -522M-74.8% | -299M-50.4% | |
| Accumulated other comprehensive income | 1.59M+141.0% | -3.87M-2263.7% | 179K+149.6% | -361K-49.8% | -241K | |
| Total liabilities & equity | 3.00B-14.5% | 3.51B+149.4% | 1.41B+39.9% | 1.01B+210.2% | 324M-17.4% | |
| Common shares issued | 131M+4.9% | 125M+31.0% | 95.4M+20.0% | 79.5M+49.9% | 53.0M+3.8% | |
| Common shares outstanding | 131M+4.9% | 125M+31.0% | 95.4M+20.0% | 79.5M+49.9% | 53.0M+3.8% | |
| Shares outstanding (cover) | 144M+11.8% | 129M+18.8% | 108M+35.5% | 80.0M+42.1% | 56.3M+9.7% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -656M-44.8% | -453M-52.5% | -297M-74.0% | -171M-40.5% | -121M-160.3% | ||
| Depreciation & amortization | 16.4M+134.1% | 7.00M+121.9% | 3.16M+11.4% | 2.83M+57.4% | 1.80M+28.1% | |
| Share-based compensation | 139M+63.7% | 84.8M+74.0% | 48.8M+106.2% | 23.6M+120.4% | 10.7M+97.4% | |
| Change in payables | 19.9M-42.4% | 34.6M+208.1% | 11.2M+287.6% | 2.90M+123.2% | -12.5M-147.8% | |
| 437M+121.8% | -2.01B-159.4% | -773M-1136.8% | 74.6M+135.1% | -212M-19113.4% | ||
| Capital expenditure | 13.7M-38.9% | 22.4M+39.6% | 16.1M+175.0% | 5.84M-10.9% | 6.55M+467.5% | |
| Free cash flow | -669M-40.9% | -475M-51.8% | -313M-77.3% | -176M-37.9% | -128M-167.8% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales/maturities of investments | 1.53B+35.1% | 1.13B+85.2% | 612M+262.7% | 169M+67.9% | 101M | |
| Proceeds from sale of PP&E | — | — | 0.00-100.0% | 7.00K-73.1% | 26.0K-48.0% | |
| 2.01M-99.9% | 2.45B+282.7% | 640M-25.7% | 862M+4741.2% | 17.8M-95.3% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00-100.0% | 196M+115.9% | 90.7M-6.7% | 97.3M+600.2% | 13.9M | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 2.44M+472.5% | 426K+106.4% | -6.69M-4980.3% | 137K+131.2% | -439K-604.6% | |
| Net change in cash | -214M-2184.1% | -9.36M+97.9% | -437M-157.1% | 766M+342.0% | -316M-196.7% | |
| Interest paid | — | — | 0.00-100.0% | 2.00K-71.4% | 7.00K+0.0% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 6.64B-37.0% | 10.5B+76.4% | 5.98B+57.8% | 3.79B+182.7% | 1.34B-1.8% | |
| P/B | 2.5×-22.4% | 3.2×-25.2% | 4.3×-59.6% | 10.5×+123.5% | 4.7×+19.6% | |
| Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: PCVX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all PCVX filings on SEC EDGAR → Not investment advice.